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Rare germline mutations of macrophage scavenger receptor 1 (MSR1) gene were reported to be associated with
prostate cancer risk in families with hereditary prostate cancer (HPC) and in patients with non-HPC (Xu et al.
2002). To further evaluate the role ofMSR1 in prostate cancer susceptibility, at Johns Hopkins Hospital, we studied
five common variants of MSR1 in 301 patients with non-HPC who underwent prostate cancer treatment and in
250 control subjects who participated in prostate cancer–screening programs and had normal digital rectal ex-
amination and PSA levels (!4 ng/ml). Significantly different allele frequencies between case subjects and control
subjects were observed for each of the five variants (P value range .01–.04). Haplotype analyses provided consistent
findings, with a significant difference in the haplotype frequencies from a global score test ( ). Because thePp .01
haplotype that is associated with the increased risk for prostate cancer did not harbor any of the known rare
mutations, it appears that the observed association of common variants and prostate cancer risk are independent
of the effect of the known rare mutations. These results consistently suggest that MSR1 may play an important
role in prostate carcinogenesis.
The macrophage scavenger receptor 1 (MSR1 [MIM
153622]) gene was recently identified as a candidate gene
for prostate cancer susceptibility, from a systematic
search for prostate cancer (MIM 176807) genes at 8p,
using multiple approaches such as linkage, direct se-
quencing, and association studies (Xu et al. 2002). Anal-
ysis of the MSR1 gene sequence in members of families
with hereditary prostate cancer (HPC) identified six rare
missense mutations (Pro36Ala, Ser41Tyr, Val113Ala,
Asp174Tyr, Gly369Ser, and His441Arg) and one non-
sense mutation (Arg293X). A family-based linkage and
association test provided statistical evidence that these
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mutations cosegregate with prostate cancer (Pp
). Further examination of these mutations in a col-.0007
lection of patients with non-HPC and unaffected men
revealed that they were either not observed or were ob-
served less frequently in men without prostate cancer.
For white men, the rare MSR1 mutations were detected
in 4.4% of cases, compared to 0.8% in unaffected men
( ); for African American men, these valuesPp .009
were 12.50% and 1.82%, respectively ( ). ThesePp .01
results provide genetic evidence thatMSR1 may play an
important role in prostate cancer susceptibility in both
African American men and men of European descent.
The MSR1 protein, a Class A scavenger receptor, is a
multidomain trimeric molecule composed of identical
protein chains. It has two functional isoforms (Type I
and Type II) and one nonfunctional isoform (Type III),
generated by alternative splicing of a single 11-exon
mRNA (Kodama et al. 1990; Emi et al. 1993). This
macrophage-specific receptor is capable of binding a
highly diverse array of polyanionic ligands, ranging from
gram negative and positive bacteria and oxidized LDL
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Table 1
Pairwise Linkage Disequilibrium (Correlation Coefficient) in
Patients With Prostate Cancer and in Unaffected Control
Subjects
PRO3 INDEL1 IVS5-59 P275A INDEL7
PRO3 .99a .59a .03 .04
INDEL1 .98a .58a .03 .04
IVS-59 .69a .71a .08 .08
P275A .06 .05 .06 .86a
INDEL7 .03 .02 .07 .73a
NOTE.—Estimates in the upper right are for control subjects
and in the lower left are for case subjects.
a Indicates , which was based on the permutationP ! .00001
tests of exact test statistics using GDA.
Table 2
Frequencies of MSR1 Sequence Variants in Patients
with Prostate Cancer and Unaffected Control Subjects
SNP, (POSITION),a
AND GENOTYPE
NO. (%) OF SUBJECTS WITH
GENOTYPE
Control Subjects Case Subjects
PRO3 (-14,742):
AA 214 (85.6) 235 (78.1)
AG 34 (13.6) 58 (19.3)
GG 2 (.8) 8 (2.6)
INDEL1b (-14,458):
/ 211 (85.4 233 (78.4)
-/ 33 (13.4) 58 (19.5)
/ 3 (1.2) 6 (2.0)
IVS5-59 (22,788):
CC 232 (92.8) 262 (87.3)
CA 18 (7.2) 34 (11.3)
AA 0 (.0) 4 (1.3)
P275A (22,850):
CC 209 (83.6) 271 (90.3)
CG 38 (15.2) 28 (9.3)
GG 3 (1.2) 1 (.3)
INDEL7 (34,504):c
/ 204 (82.9) 264 (88.9)
/ 41 (16.7) 33 (11.1)
/ 1 (.4) 0 (.0)
a Positions (bp) are based on the initiation codon (ATG)
from MSR1 genomic DNA (NT_015280).
b “” and “” denote with and without the 15-bp
sequence “GAATGCTTTATTGTA,” respectively.
c “” and “” denote with and without the 3-bp se-
quence “TTA,” respectively.
to silica, and, correspondingly, has been linked to a wide
variety of normal and pathological processes, including
inflammation, innate and adaptive immunity, oxidative
stress, and apoptosis (Platt and Gordon 2001). Although
the exact role of MSR1 in prostate carcinogenesis is un-
known, some or all of these processes have been impli-
cated in the development of prostate cancer (De Marzo
et al. 1999; Nelson et al. 2001). Recent findings showing
that the degree of macrophage infiltration is associated
with prostate cancer prognosis strengthen the link be-
tween MSR1 and prostate cancer (Lissbrant et al. 2000;
Shimura et al. 2000).
Besides the seven rare MSR1 mutations we reported
elsewhere (Xu et al. 2002), we identified four additional
common sequence variants (110%) after sequencing the
PCR products of all 11 exons, exon-intron junctions,
promoter region, and 5′ and 3′ UTRs of MSR1 in the
germline DNA of probands from each of the 159 families
with HPC (i.e., at least three first-degree relatives af-
fected with prostate cancer). Together with the common
missense change we identified elsewhere (Xu et al. 2002),
there are five common sequence variants in our se-
quenced regions.
To evaluate the role of MSR1 sequence variants in
prostate cancer susceptibility as it relates to the general
population, we focused this study on the common se-
quence variants and patients with prostate cancer who
do not meet criteria for HPC. Because of the limited
number of African Americans in our study, all the fol-
lowing analyses were restricted to men of European de-
scent. Five common sequence variants were genotyped
in 301 patients with prostate cancer and in 250 unaf-
fected control subjects. The case subjects were recruited
from the patients who underwent prostate cancer treat-
ment at Johns Hopkins Hospital and did not meet the
criteria for HPC ( ). The diagnosis of prostateNp 317
cancer was confirmed by pathology reports, and the
mean age at diagnosis was 59.3 years. Sixteen patients
were excluded from the current study because of insuf-
ficient DNA. The control subjects were recruited from
volunteers participating in prostate cancer–screening
programs at Johns Hopkins Hospital who had a normal
digital rectal examination and PSA (!4 ng/ml) (Np
). The mean age at examination was 58.5 years. Six256
control subjects were excluded from the current study
because of insufficient DNA. All subjects in this study
gave full informed consent.
The five sequence variants genotyped in this study
include an SNP in the promoter region (PRO3), a 15-
bp insertion/deletion of “GAATGCTTTATTGTA” in
intron 1 (INDEL1), an SNP in intron 5 (IVS5-59), a
missense change in exon 6 (P275A), and a 3-bp insertion/
deletion of “TTA” in intron 7 (INDEL7). The positions
of these sequence variants are listed in table 2. Geno-
typing of the three SNPs (PRO3, IVS-59, and P275A)
was performed using the MassARRAY system (SE-
QUENOM). Genotyping of the two insertion/deletions
(INDEL1 and INDEL7) was performed using the 3700
DNA Analyzer (Applied Biosystems). The primer infor-
mation and detailed PCR conditions for these sequence
variants are available on the authors’ Web site.
All five sequence variants were in Hardy-Weinberg
equilibrium in control subjects, on the basis of 10,000
permutations of the Fisher probability test statistic (Weir
1996), as implemented in the softwareGeneticDataAnal-
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Table 3
Allele Frequencies in Patients with Prostate Cancer
and Unaffected Control Subjects
ALLELE
ALLELE FREQUENCIES (%)
x2 TEST
FOR ALLELE
(P VALUES)Control Subjects Case Subjects
PRO3 “G” 7.6 12.3 .01
INDEL1 “”a 7.9 11.8 .04
IVS5-59 “A” 3.6 7.0 .02
P275A “C” 91.2 95.0 .01
INDEL7 “”b 91.3 94.4 .04
a “” denotes the presence of the 15-bp sequence
“GAATGCTTTATTGTA.”
b “” denotes the absence of the 3-bp sequence “TTA.”
Table 4
Odds Ratio (OR) Estimates for
Prostate Cancer, Adjusting for Age
Variant: Genotypes OR (95% CI)
PRO3:
AA 1.00
AG/GG 1.81 (1.15–2.85)
INDEL1:
/ 1.00
/ or / 1.73 (1.10–2.72)
IVS-59:
CC 1.00
CA/AA 1.93 (1.07–3.50)
P275A:
CG/GG 1.00
CC 1.75 (1.05–2.94)
INDEL7:
/ 1.00
/ or / 1.54 (.94–2.52)
NOTE.—OR estimates are adjusted
for age.
ysis (GDA). The first three sequence variants (PRO3, IN-
DEL1, and IVS5-59) were in strong linkage disequilib-
rium (LD), because the tests for pairwise LD among them
were all highly significant (all ), again on theP ! .00001
basis of 10,000 permutations of the exact test statistic
(Weir 1996), as implemented in GDA. The last two var-
iants also had strong LD between them ( ).P ! .00001
There was no LD between the blocks of the first three
variants and the last two variants (all ). The es-P 1 .2
timates of pairwise LD between all these sequence var-
iants in case subjects and control subjects, as measured
by correlation coefficients and implemented in SAS/Ge-
netics, are presented in table 1.
The allele frequencies of the five sequence variants
were all significantly different between case subjects and
control subjects, on the basis of a x2 test for allele fre-
quencies, with 1 df (table 2; table 3). Specifically, the
frequency of allele “G” of PRO3 ( ), 15-bp in-Pp .01
sertion () of INDEL1 ( ), allele “A” of IVS5-Pp .04
59 ( ), allele “C” of P275A ( ), and de-Pp .02 Pp .01
letion () of INDEL7 ( ), were higher in casePp .04
subjects than in control subjects, respectively. To esti-
mate the prostate cancer risk of these variants, we per-
formed the tests by grouping three genotypes into two
genotypes as shown in table 4. Except for the INDEL7,
there were significant elevated risks for prostate cancer
among the sequence variants, even when adjusted for
age.
The haplotype analysis of these five sequence variants
using the EM algorithm (Excoffier and Slatkin 1995)
estimated that four major haplotypes account for 196%
of all haplotypes (table 5). The haplotype frequencies
were significantly different between case subjects and
control subjects, with a P value of .011 from 10,000
simulations of global score tests, as implemented in
haplo.score (Schaid et al. 2002). When specific haplo-
types were examined, the haplotype “G () A C ()”
of these five variants (in the order of PRO3, INDEL1,
IVS5-59, P275A, and INDEL7) had a significantly
higher frequency in prostate cancer patients (6.6%) than
in control subjects (2.6%), with a P value of .004 (on
the basis of 10,000 simulations). It is worth noting that
this haplotype did not harbor any of the rare mutations
(Arg293X, His441Arg, Val113Ala, and Ile54Val) (Xu et
al. 2002). For example, all eight occurrences of Arg293X
and three occurrences of His441Arg resided on the hap-
lotype “A () C C ().” Therefore, it appears that the
significant association between the common MSR1 se-
quence variants and prostate cancer risk is independent
of the impact of the known rare MSR1 mutations.
Caution should be taken when interpreting these find-
ings. Although the significant differences in allele and
haplotype frequencies between patients with prostate
cancer and unaffected control subjects could be due to
the prostate cancer risk associated with these polymor-
phisms, it could also be due to other reasons, such as a
type I error or population stratification. Regarding type
I error, all the reported significance levels were nominal
P values and were not adjusted for multiple compari-
sons. If we considered that at least 15 tests were per-
formed in this report, and that the commonly suggested
Bonferoni correction was used, none of the tests was
significant at . However, the Bonferoni correc-Pp .05
tion is not optimal in this case; not all of these tests were
independent because of the LD between these polymor-
phisms and the dependence between allele and haplo-
type. Regarding population stratification, the results, as
a case-control study, are always subject to this potential
confounder: that is, the different genotype frequencies
observed may partially reflect different genetic back-
grounds in case subjects and control subjects. Although
great attention was paid in the study design and analysis,
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Table 5
Haplotype Frequencies of MSR1 Sequence Variants in Patients with Prostate Cancer
and Unaffected Control Subjects
HAPLOTYPEa
FREQUENCY (95% CI) P VALUES (EMPIRICAL)
Control Subjects Case Subjects Haplotype Specific
A () C C () 83.6% (80.3–86.9) 81.8% (78.7–84.9) .44
G () A C () 2.6% (1.2–4.0) 6.6% (4.6–8.6) .004
A () C G () 6.5% (4.3–8.6) 4.0% (2.4–5.5) .06
G () C C () 3.7% (2.1–5.4) 4.1% (2.5–5.7) .77
Global .011
a Haplotype of five SNPs (in the order of PRO3, INDEL1, IVS-59, P275A, and
INDEL7)
including the restriction to subjects of European descent
only, we cannot rule out the possibility of population
stratification.
Each of these five sequence variants could have an
important impact on MSR1 function. For example, the
SNP in the promoter region and the 15-bp ins/del poly-
morphism could affect transcription of the MSR1 gene.
The missense change of Pro275Ala could affect the func-
tion of theMSR1 protein, because it changes a conserved
residue in the first Gly-X-Y repeat of the collagenous
domain of the protein. However, because all five se-
quence variants were associated with prostate cancer
risk, and the risk haplotype “G () A C ()” included
all the risk alleles for each variant, it is difficult to dissect
genetically which variant(s) are the most important
changes. It is possible that one or more of these variants
are associated with prostate cancer risk. Future func-
tional analyses using various combinations of these var-
iants may help to confirm these findings and provide
insight into the function of each variant.
The results from this study and the study of MSR1
rare mutations (Xu et al. 2002) suggest that rare mu-
tations and common sequence variants of MSR1 confer
differential risks of prostate cancer. Although the rare
MSR1 mutations tend to impose relatively high risk of
prostate cancer, common MSR1 sequence variants
within the same major genes tend to have a relatively
low risk of prostate cancer. Similar observations were
observed in two other major prostate cancer suscepti-
bility genes, HPC2/ELAC2 (MIM 605367) and RNA-
SEL (MIM 180435) (Tavtigian et al. 2001; Carpten et
al. 2002). For example, two rare mutations (E265X and
M1I) of the ribonuclease L gene (RNASEL) were rare
and observed mainly in families with HPC; another com-
mon sequence variant (Arg462Gln) was frequent in pop-
ulation and imposed intermediate risk to prostate cancer
(Wang et al. 2002).
In summary, the significant differences in the allele and
haplotype frequencies between patients with non-HPC
and unaffected control subjects observed in this study
suggest that common MSR1 sequence variants are as-
sociated with prostate cancer risk in the general popu-
lation. Together with evidence that the rare MSR1 mu-
tations are associated with increased prostate cancer
susceptibility in patients with HPC and with non-HPC
(Xu et al. 2002), the role of MSR1 and macrophages in
prostate carcinogenesis is implicated. However, inde-
pendent studies are extremely important to support these
findings, given the complexity of prostate cancer.
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